Cargando…
Inhibition of p70 S6 Kinase (S6K1) Activity by A77 1726 and Its Effect on Cell Proliferation and Cell Cycle Progress()()
Leflunomide is a novel immunomodulatory drug prescribed for treating rheumatoid arthritis. It inhibits the activity of protein tyrosine kinases and dihydroorotate dehydrogenase, a rate-limiting enzyme in the pyrimidine nucleotide synthesis pathway. Here, we report that A77 1726, the active metabolit...
Autores principales: | Doscas, Michelle E., Williamson, Ashley J., Usha, Lydia, Bogachkov, Yedida, Rao, Geetha S., Xiao, Fei, Wang, Yimin, Ruby, Carl, Kaufman, Howard, Zhou, Jingsong, Williams, James W., Li, Yi, Xu, Xiulong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212247/ https://www.ncbi.nlm.nih.gov/pubmed/25379019 http://dx.doi.org/10.1016/j.neo.2014.08.006 |
Ejemplares similares
-
Inhibition of p70 S6 kinase (S6K1) activity by A77 1726, the active metabolite of leflunomide, induces autophagy through TAK1-mediated AMPK and JNK activation
por: Xu, Xiulong, et al.
Publicado: (2017) -
Inhibition of p70 S6 kinase activity by A77 1726 induces autophagy and enhances the degradation of superoxide dismutase 1 (SOD1) protein aggregates
por: Sun, Jing, et al.
Publicado: (2018) -
The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function
por: Kirsch, Bernhard M, et al.
Publicado: (2005) -
Inhibition of porcine epidemic diarrhea virus (PEDV) replication by A77 1726 through targeting JAK and Src tyrosine kinases
por: Li, Xiaomei, et al.
Publicado: (2020) -
Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels
por: Fajardo-Robledo, Nicte S., et al.
Publicado: (2022)